FDA Recalls libigrow RED DRAGON+ Capsules for Undeclared Sildenafil and Tadalafil
Pyramids Wholesale Inc. is recalling libigrow RED DRAGON+ capsules nationwide because they contain undeclared sildenafil and tadalafil, prescription medications not approved by the FDA for this product.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class I recall, which establishes a minimum severity of Severe per the rubric. The product contains undeclared prescription drugs without FDA approval, creating potential health risks. No illnesses or injuries have been reported.
Plain-English summary
The FDA has issued a Class I recall of libigrow RED DRAGON+ (2 capsules per box, UPC 7 05105 83073 5), manufactured by Pyramids Wholesale Inc. The product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) and contains undeclared sildenafil and tadalafil, both of which are prescription medications.
The affected product has been distributed nationwide in the United States, and all lots are included in this recall.
Consumers who have obtained this product should stop using it immediately. If you have taken this product, consult your healthcare provider. Do not discard in household trash; contact a pharmacy or local waste disposal facility for proper disposal instructions.
The recalled product
- Product
- libigrow RED DRAGON+, Maximum Strength Formula, 2 capsules per box, UPC 7 05105 83073 5.
- Manufacturer
- Pyramids Wholesale Inc.
- Category
- Drug
- Hazard
- sildenafil
- tadalafil
- unapproved-drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27